UnitedHealth Q3 EPS Beats, Full-Year Guidance Raised to at Least $20.50 Adjusted
UNH sits 52% above its 52-week low of $255.965.
Summary
UnitedHealth beat Q3 estimates with adjusted EPS of $4.69 and raised full-year 2026 guidance to at least $20.50 per share, driven by improved medical cost management and strong cash flow. Management said 2027 analyst consensus may understate opportunity, seeing the lower end of 13-16% growth as a more reasonable starting point.
Updated with a Benzinga report · What changed
Updates
· Benzinga — Management said 2027 analyst consensus may understate opportunity, seeing lower end of 13-16% growth as more reasonable starting point.
- 2026 Guidance — Previous 2026 adjusted earnings guidance was $19.50 to $20 per share.
- Medical Cost Drivers — Medical care ratio improvement was credited to plan design and new pricing. Medical costs remain high in specialty pharmacy and acute care, with commercial cost trends above 11%.
- No Surprises Act
- Ongoing abuse of the No Surprises Act dispute process by clinician groups and third-party organizations.
- Arbitration awards under the No Surprises Act can run 10 to 11 times what Medicare would pay.
- Margin Outlook — High utilization will stretch out achieving long-term commercial margins. Medicare Advantage margins are expected near the top of the 2% to 4% range. 2026 is a trough year for core Medicaid margins, which should come in moderately better than minus 1%.
- Membership Guidance — Formal membership and enrollment guidance for Medicare and insurance plans is held back until an investor meeting before year-end.
All 11 details
- Previous 2026 adjusted earnings guidance was $19.50 to $20 per share.
- Medical care ratio improvement was also credited to plan design and new pricing.
- Medical costs remain stubbornly high, particularly in specialty pharmacy and acute healthcare service intensity.
- Ongoing abuse of the No Surprises Act dispute process by clinician groups and third-party organizations.
- Arbitration awards under the No Surprises Act can run 10 to 11 times what Medicare would pay.
- Commercial cost trends are running above 11%.
- High utilization will stretch out the ability to achieve long-term objective margins in the commercial business.
- Company expects Medicare Advantage margins near the top of its 2% to 4% range.
- Company called 2026 a trough year for core Medicaid margins.
- Core Medicaid margins should come in moderately better than minus 1%.
- Management held back formal membership and enrollment guidance for Medicare and insurance plans until an investor meeting before year-end.
Key Events · Earnings and Guidance · UNH
-
New · · Benzinga
Management Sees 2027 Consensus Understating Opportunity
Management said 2027 analyst consensus may understate opportunity, seeing the lower end of 13-16% growth as a more reasonable starting point.
-
New · · Benzinga
Medical Costs Remain High
Medical costs remain stubbornly high, particularly in specialty pharmacy and acute healthcare service intensity. Commercial cost trends are running above 11%.
-
New · · Benzinga
No Surprises Act Abuse Cited
Ongoing abuse of the No Surprises Act dispute process by clinician groups and third-party organizations was cited. Arbitration awards under the No Surprises Act can run 10 to 11 times what Medicare would pay.
-
New · · Benzinga
Margin Expectations Detailed
Company expects Medicare Advantage margins near the top of its 2% to 4% range. Company called 2026 a trough year for core Medicaid margins, which should come in moderately better than minus 1%.
-
New · · Benzinga
High Utilization Stretches Commercial Margin Timeline
High utilization will stretch out the ability to achieve long-term objective margins in the commercial business.
-
New · · Benzinga
Membership Guidance Withheld
Management held back formal membership and enrollment guidance for Medicare and insurance plans until an investor meeting before year-end.
-
Updated · · Benzinga
Full-Year Guidance Raised to at Least $20.50
Company now expects full-year 2026 adjusted net earnings of at least $20.50 per share and GAAP EPS of at least $19.50, incorporating experience through Q3. Previous 2026 adjusted earnings guidance was $19.50 to $20 per share.
-
Updated · · Benzinga
Medical Cost Ratio Improves
Medical care ratio fell to 88.4% from 89.9% a year ago, aided by $610 million of net favorable prior-period reserve development related to 2026 dates of service. Improvement was also credited to plan design and new pricing.
-
Q3 Adjusted EPS of $4.69 Beats
Adjusted earnings of $4.69 per share compared to $2.92 in Q3 2025; GAAP EPS was $4.56. Revenues were $112.7 billion, essentially flat year-over-year.
-
Strong Cash Flow and Capital Returns
Cash flows from operations were $5.1 billion (1.2x net income). Year-to-date, the company repurchased $5.0 billion of stock and paid $6.2 billion in dividends.
Analysis · UNH · Finance
UnitedHealth delivered Q3 adjusted EPS of $4.69, well above the year-ago $2.92, and raised full-year 2026 adjusted guidance to at least $20.50 per share, up from the previous $19.50 to $20 per share. The medical care ratio improved to 88.4% from 89.9% a year ago, helped by $610 million of favorable prior-period reserve development, plan design, and new pricing. Cash flow remains strong at $5.1 billion, and the company returned $11.2 billion to shareholders year-to-date through buybacks and dividends. The beat comes despite continued membership contraction — UnitedHealthcare served 48.3 million people, down from 50.1 million a year ago — and against a backdrop of regulatory scrutiny and a recent drop in Medicare Advantage star ratings. Management said 2027 analyst consensus may understate opportunity, seeing the lower end of 13-16% growth as a more reasonable starting point, while noting medical costs remain stubbornly high, particularly in specialty pharmacy and acute healthcare service intensity, and commercial cost trends are running above 11%. High utilization will stretch out the ability to achieve long-term objective margins in the commercial business.
How filings like this one have moved
In the 30 days to Oct 13, 2026, 36.5% of the 995 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, UNH was trading at $388.51 on NYSE in the Finance sector, with a market capitalization of approximately $339.8B. The 52-week trading range was $255.97 to $461.62. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.